시장보고서
상품코드
2111324

세포 및 유전자 치료 바이오 제조 시장 보고서(2026년)

Cell And Gene Therapy Bio-Manufacturing Global Market Report 2026

발행일: | 리서치사: 구분자 The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 4,490 금액 안내 화살표 ₩ 6,324,000
PDF & Excel (Site License) help
PDF & Excel 보고서를 동일 기업의 동일 사업장 내의 모든 분이 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 6,490 금액 안내 화살표 ₩ 9,141,000
PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 8,490 금액 안내 화살표 ₩ 11,958,000
※ 부가세 별도
한글목차
영문목차

세포 및 유전자 치료 바이오 제조 시장 규모는 최근 급성장하고 있습니다. 2025년 123억 5,000만 달러에서 2026년에는 138억 3,000만 달러로, CAGR 12.0%로 성장할 전망입니다. 이러한 성장은 단일클론 항체 및 바이오의약품 개발의 급속한 진전, 유전자 치료 초기 연구에 대한 투자 확대, 바이오기술 제조 인프라 확충, 만성 질환 및 유전성 질환의 유병률 상승, 그리고 첨단 치료법에 대한 규제 체계 정비 등에 기인한 것으로 보입니다.

세포 및 유전자 치료 바이오 제조 시장 규모는 향후 몇 년간 급성장이 전망되고 있습니다. 2030년에는 214억 6,000만 달러에 이르고, CAGR은 11.6%를 나타낼 전망입니다. 예측 기간 동안의 이러한 성장은 유전자·세포 치료의 상용화 진전, 확장 가능한 바이러스 벡터 생산에 대한 수요 증가, 맞춤형 의료의 보급 확대, 위탁 개발·제조 기관(CDMO)의 성장, 바이오 제조 시설의 자동화 및 디지털화 진전에 기인한 것으로 보입니다. 예측 기간 동안의 주요 동향으로는 세포 치료제 제조에 있어 일회용 바이오프로세싱 시스템의 채택 확대, 자동화 및 밀폐형 세포 처리 플랫폼에 대한 수요 증가, 첨단 바이러스 벡터 생산 기술의 활용 확대, 맞춤형 치료 및 자가 치료 제조 파이프라인의 확대, 디지털 바이오 제조와 데이터 기반 품질 관리의 통합 진전 등이 꼽힙니다.

세포 및 유전자 치료의 승인 건수 증가는 향후 세포 및 유전자 치료 바이오 제조 시장의 성장을 뒷받침할 것으로 예측됩니다. 세포 및 유전자 치료란, 변형된 세포나 유전 물질을 이용하여 암, 희귀 유전성 질환, 만성 질환 등의 질환을 치료, 예방 또는 근치할 수 있는 첨단 의료 치료를 말합니다. 세포 및 유전자 치료의 승인 건수가 증가하고 있는 배경에는 CRISPR 등의 유전공학 기술의 급속한 발전, 질환의 생물학적 메커니즘에 대한 이해 심화, 보다 안전하고 효과적인 표적 치료를 가능하게 하는 전달 시스템의 개선이 있습니다. 세포 및 유전자 치료의 승인은 투자 가속화, 생산 인프라 확충, 임상 및 상업적 용도로 안전하고 효과적인 치료제를 안정적으로 생산하는 데 필요한 표준화되고 고품질이며 규제를 준수하는 제조 공정의 개발을 촉진함으로써 세포 및 유전자 치료 바이오 제조를 뒷받침하고 있습니다. 예를 들어, 2024년 1월, 미국에 기반을 둔 유전자· 세포 치료 관련 단체인 미국 유전자·세포 치료 학회(American Society of Gene and Cell Therapy)에 따르면, 2023년 4분기 유전자 치료의 3상 임상시험 건수는 전 분기 대비 10% 증가하여 2022년 3분기 이후 처음으로 증가세를 보였습니다. 따라서 세포 및 유전자 치료의 승인 건수 증가가 세포 및 유전자 치료 바이오 제조 시장의 성장을 견인하고 있습니다.

세포 및 유전자 치료 바이오 제조 시장에서 사업을 전개하는 주요 기업들은 확장성 향상, 개발 기간 단축, 첨단 치료법의 임상 및 상업 생산에서의 일관성 향상을 도모하기 위해 모듈식 렌티바이러스 벡터 제조 시스템 등 혁신적인 시스템 개발에 주력하고 있습니다. 모듈형 렌티바이러스 벡터 제조 시스템은 표준화되고 확장성이 뛰어난 플랫폼으로, 미리 정의된 생산 모듈을 사용하여 GMP 조건 하에서 렌티바이러스 벡터를 제조합니다. 이를 통해 일관성 향상, 편차 감소, 연구 단계부터 임상 및 상업 생산에 이르는 개발 가속화가 도모됩니다. 예를 들어, 2026년 5월, 미국에 기반을 둔 위탁 개발·제조 기관(CDMO)인 Andelyn Biosciences는 세포 및 유전자 치료제 생산을 효율화하기 위해 설계된 표준화된 렌티바이러스 벡터 제조 시스템인 ‘LVV Curator’ 플랫폼을 출시했습니다. 이 플랫폼은 100건 이상의 아데노연관바이러스(AAV) 프로그램을 지원해 온 검증된 ‘Curator’ 조사 기법에 기반하여 구축된, 모듈식이며 사전 검증된 프레임워크를 활용하여 개발 속도를 높이고 공정 위험을 줄입니다. 개념 단계부터 임상 단계에 이르기까지 렌티바이러스 벡터의 공정을 산업화하도록 설계되어, 개발의 복잡성을 최소화하면서 확장성, 생산성, 제품 순도를 향상시킵니다.

자주 묻는 질문

  • 세포 및 유전자 치료 바이오 제조 시장 규모는 어떻게 변할 것으로 예상되나요?
  • 세포 및 유전자 치료 바이오 제조 시장의 성장은 어떤 요인에 기인하나요?
  • 세포 및 유전자 치료의 승인 건수 증가는 시장에 어떤 영향을 미치나요?
  • 세포 및 유전자 치료 바이오 제조 시장에서 주요 기업들은 어떤 혁신을 추구하고 있나요?
  • 모듈식 렌티바이러스 벡터 제조 시스템의 특징은 무엇인가요?

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교와 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 시장에서 주목 받는 스타트업

제40장 주요 인수합병(M&A)

제41장 시장 잠재력이 높은 국가, 전략

제42장 부록

JHS 26.08.20

Cell and gene therapy bio-manufacturing refers to the industrial-scale production processes used to develop, expand, and manufacture advanced therapeutic products based on living cells and genetic material. It involves the controlled modification, cultivation, and processing of cells or genetic components to produce therapies intended to treat, prevent, or potentially cure diseases by targeting underlying biological mechanisms. These manufacturing processes require highly specialized facilities, precision engineering, and rigorous quality control measures to ensure product safety, effectiveness, and regulatory compliance.

The primary product types of cell and gene therapy bio-manufacturing include bioreactors and fermenters, cell processing systems, viral vector production systems, consumables and reagents, and software and automation platforms. Bioreactors and fermenters refer to controlled systems designed for the growth, expansion, and processing of cells and biological materials under regulated conditions. These systems are based on technologies including viral vector-based manufacturing, non-viral gene delivery systems, autologous cell therapy production, allogeneic cell therapy production, and stem cell-based manufacturing. The key applications include upstream processing, harvesting, and downstream processing, while the end users include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, academic and research institutes, and hospitals and clinical centers.

Tariffs are influencing the cell and gene therapy bio-manufacturing market by increasing the cost of imported bioprocessing equipment, single-use consumables, and advanced laboratory instrumentation required for production. This is increasing operational expenses for pharmaceutical and biotechnology companies and slowing expansion of manufacturing capacity, particularly in import-dependent regions such as Asia-Pacific and Europe. Viral vector production systems and cell processing equipment segments are most affected due to their reliance on highly specialized global supply chains. However, tariffs are also encouraging regional manufacturing of bioprocessing components, localization of critical raw materials, and increased investment in domestic biotech infrastructure, ultimately supporting long-term supply chain resilience and reducing dependency on international suppliers.

The cell and gene therapy bio-manufacturing market size has grown rapidly in recent years. It will grow from $12.35 billion in 2025 to $13.83 billion in 2026 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to rapid growth in monoclonal antibody and biologics development, increasing investment in early gene therapy research, expansion of biotechnology manufacturing infrastructure, rising prevalence of chronic and genetic diseases, development of regulatory frameworks for advanced therapies.

The cell and gene therapy bio-manufacturing market size is expected to see rapid growth in the next few years. It will grow to $21.46 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing commercialization of gene and cell therapies, rising demand for scalable viral vector production, expansion of personalized medicine adoption, growth in contract development and manufacturing organizations, increasing automation and digitalization of biomanufacturing facilities. Major trends in the forecast period include increasing adoption of single use bioprocessing systems in cell therapy manufacturing, growing demand for automated and closed system cell processing platforms, rising use of advanced viral vector production technologies, expansion of personalized and autologous therapy manufacturing pipelines, increasing integration of digital biomanufacturing and data driven quality control.

The increasing number of cell and gene therapy approvals is expected to propel the growth of the cell and gene therapy bio-manufacturing market going forward. Cell and gene therapies refer to advanced medical treatments that use modified cells or genetic material to treat, prevent, or potentially cure diseases, including cancer, rare genetic disorders, and chronic conditions. The increasing number of cell and gene therapy approvals is driven by rapid advancements in genetic engineering technologies such as CRISPR, a better understanding of disease biology, and improved delivery systems that enable safer and more effective targeted treatments. Cell and gene therapy approvals support cell and gene therapy bio-manufacturing by accelerating investment, expanding production infrastructure, and promoting the development of standardized, high-quality, and regulatory-compliant manufacturing processes required to consistently produce safe and effective therapies for clinical and commercial use. For instance, in January 2024, according to the American Society of Gene and Cell Therapy, a US-based organization for gene and cell therapy, in the fourth quarter of 2023, the number of gene therapies in Phase III increased by 10% compared to the previous quarter, marking the first increase since the third quarter of 2022. Therefore, the increasing number of cell and gene therapy approvals is driving the growth of the cell and gene therapy bio-manufacturing market.

Key companies operating in the cell and gene therapy bio-manufacturing market are focusing on developing innovative systems, such as modular lentiviral vector manufacturing systems, to enhance scalability, reduce development timelines, and improve consistency in clinical and commercial production of advanced therapies. Modular lentiviral vector manufacturing systems are standardized, scalable platforms that use predefined production modules to manufacture lentiviral vectors under GMP conditions, helping improve consistency, reduce variability, and accelerate development from research to clinical and commercial production. For example, in May 2026, Andelyn Biosciences, a US-based contract development and manufacturing organization (CDMO), launched its LVV Curator platform, a standardized lentiviral vector manufacturing system designed to streamline cell and gene therapy production. The platform leverages a modular and pre-validated framework built on proven Curator methodology that has supported over 100 adeno-associated virus (AAV) programs, enabling faster development and reduced process risk. It is designed to industrialize lentiviral vector processes from concept to clinic, improving scalability, productivity, and product purity while minimizing development complexity.

In January 2024, Oxford Biomedica plc, a UK-based healthcare and biotechnology company, acquired ABL Europe SAS for $17.35 million. Through this acquisition, Oxford Biomedica plc aimed to strengthen its position as a global leader in cell and gene therapy manufacturing by expanding its viral vector development and production capabilities, increasing its manufacturing footprint across Europe, and enhancing its capacity to serve biopharma clients with advanced gene therapy solutions. ABL Europe SAS is a France-based contract development and manufacturing organization (CDMO) that specializes in providing viral vector development, manufacturing, and testing services for gene therapies, vaccines, and oncolytic virus-based treatments.

Major companies operating in the cell and gene therapy bio-manufacturing market are Thermo Fisher Scientific Inc.; Merck KGaA; Lonza Group AG; Samsung Biologics Co. Ltd.; Danaher Corporation; FUJIFILM Corporation; Pfizer CentreOne; Charles River Laboratories International Inc.; Boehringer Ingelheim International GmbH; Sartorius AG; Miltenyi Biotec B.V. & Co. KG; AGC Biologics LLC; Oxford Biomedica plc; Takara Bio Inc.; KBI Biopharma Inc.; Rentschler Biopharma SE; Minaris Regenerative Medicine GmbH; ElevateBio LLC; Forge Biologics Holdings LLC; Porton Advanced Solutions Co. Ltd.; Cellares Corporation; Repligen Corporation; Asahi Kasei Medical; Thermo Fisher Scientific / Brammer Bio; WuXi Advanced Therapies; Catalent Inc.

North America was the largest region in the cell and gene therapy bio-manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy bio-manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cell and gene therapy bio-manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cell and gene therapy bio-manufacturing market consists of revenues earned by entities by providing services such as cell line development, aseptic fill-finish services, cryopreservation, and regulatory support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell and gene therapy bio-manufacturing market also includes sales of engineered cell lines, gene editing reagents, single-use bioprocessing systems, cell processing kits, and analytical assay kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The cell and gene therapy bio-manufacturing market research report is one of a series of new reports from The Business Research Company that provides cell and gene therapy bio-manufacturing market statistics, including cell and gene therapy bio-manufacturing industry global market size, regional shares, competitors with a cell and gene therapy bio-manufacturing market share, detailed cell and gene therapy bio-manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy bio-manufacturing industry. This cell and gene therapy bio-manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell And Gene Therapy Bio-Manufacturing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cell and gene therapy bio-manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cell and gene therapy bio-manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell and gene therapy bio-manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product Type: Bioreactors And Fermenters; Cell Processing Systems; Viral Vector Production Systems; Consumables And Reagents; Software And Automation Platforms
  • 2) By Technology: Viral Vector Based Manufacturing; Non Viral Gene Delivery Systems; Autologous Cell Therapy Production; Allogeneic Cell Therapy Production; Stem Cell Based Manufacturing
  • 3) By Application: Upstream Processing; Harvesting; Downstream Processing
  • 4) By End User: Pharmaceutical And Biotechnology Companies; Contract Development And Manufacturing Organizations; Academic And Research Institutes; Hospitals And Clinical Centers
  • Subsegments:
  • 1) By Bioreactors And Fermenters: Single Use Bioreactors; Stainless Steel Bioreactors; Stirred Tank Bioreactors; Wave Induced Bioreactors; Perfusion Bioreactors; Continuous Fermentation Systems
  • 2) By Cell Processing Systems: Cell Isolation Systems; Cell Expansion Systems; Cell Washing Systems; Cell Separation Systems; Automated Cell Processing Platforms; Closed System Cell Processing Equipment
  • 3) By Viral Vector Production Systems: Lentiviral Vector Production Systems; Adeno Associated Viral Vector Production Systems; Retroviral Vector Production Systems; Baculovirus Expression Systems; Transfection Systems; Viral Vector Purification Systems
  • 4) By Consumables And Reagents: Cell Culture Media; Buffers And Solutions; Filtration Consumables; Chromatography Resins; Single Use Bags And Tubing; Assay And Detection Reagents
  • 5) By Software And Automation Platforms: Manufacturing Execution Software; Laboratory Information Management Software; Process Monitoring Platforms; Data Analytics Platforms; Workflow Automation Systems; Quality Control Software
  • Companies Mentioned: Thermo Fisher Scientific Inc.; Merck KGaA; Lonza Group AG; Samsung Biologics Co. Ltd.; Danaher Corporation; FUJIFILM Corporation; Pfizer CentreOne; Charles River Laboratories International Inc.; Boehringer Ingelheim International GmbH; Sartorius AG; Miltenyi Biotec B.V. & Co. KG; AGC Biologics LLC; Oxford Biomedica plc; Takara Bio Inc.; KBI Biopharma Inc.; Rentschler Biopharma SE; Minaris Regenerative Medicine GmbH; ElevateBio LLC; Forge Biologics Holdings LLC; Porton Advanced Solutions Co. Ltd.; Cellares Corporation; Repligen Corporation; Asahi Kasei Medical; Thermo Fisher Scientific / Brammer Bio; WuXi Advanced Therapies; Catalent Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Cell And Gene Therapy Bio-Manufacturing Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Cell And Gene Therapy Bio-Manufacturing Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Cell And Gene Therapy Bio-Manufacturing Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Cell And Gene Therapy Bio-Manufacturing Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
    • 4.1.5 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Single Use Bioprocessing Systems In Cell Therapy Manufacturing
    • 4.2.2 Growing Demand For Automated And Closed System Cell Processing Platforms
    • 4.2.3 Rising Use Of Advanced Viral Vector Production Technologies
    • 4.2.4 Expansion Of Personalized And Autologous Therapy Manufacturing Pipelines
    • 4.2.5 Increasing Integration Of Digital Biomanufacturing And Data Driven Quality Control

5. Cell And Gene Therapy Bio-Manufacturing Market Analysis Of End Use Industries

  • 5.1 Pharmaceutical And Biotechnology Companies
  • 5.2 Contract Development And Manufacturing Organizations
  • 5.3 Academic And Research Institutes
  • 5.4 Hospitals And Clinical Centers
  • 5.5 Other End Users

6. Cell And Gene Therapy Bio-Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Cell And Gene Therapy Bio-Manufacturing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Cell And Gene Therapy Bio-Manufacturing PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Cell And Gene Therapy Bio-Manufacturing Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Cell And Gene Therapy Bio-Manufacturing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Cell And Gene Therapy Bio-Manufacturing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Cell And Gene Therapy Bio-Manufacturing Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Cell And Gene Therapy Bio-Manufacturing Market Segmentation

  • 9.1. Global Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Bioreactors And Fermenters, Cell Processing Systems, Viral Vector Production Systems, Consumables And Reagents, Software And Automation Platforms
  • 9.2. Global Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Viral Vector Based Manufacturing, Non Viral Gene Delivery Systems, Autologous Cell Therapy Production, Allogeneic Cell Therapy Production, Stem Cell Based Manufacturing
  • 9.3. Global Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Upstream Processing, Harvesting, Downstream Processing
  • 9.4. Global Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Pharmaceutical And Biotechnology Companies, Contract Development And Manufacturing Organizations, Academic And Research Institutes, Hospitals And Clinical Centers
  • 9.5. Global Cell And Gene Therapy Bio-Manufacturing Market, Sub-Segmentation Of Bioreactors And Fermenters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Single Use Bioreactors, Stainless Steel Bioreactors, Stirred Tank Bioreactors, Wave Induced Bioreactors, Perfusion Bioreactors, Continuous Fermentation Systems
  • 9.6. Global Cell And Gene Therapy Bio-Manufacturing Market, Sub-Segmentation Of Cell Processing Systems, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cell Isolation Systems, Cell Expansion Systems, Cell Washing Systems, Cell Separation Systems, Automated Cell Processing Platforms, Closed System Cell Processing Equipment
  • 9.7. Global Cell And Gene Therapy Bio-Manufacturing Market, Sub-Segmentation Of Viral Vector Production Systems, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Lentiviral Vector Production Systems, Adeno Associated Viral Vector Production Systems, Retroviral Vector Production Systems, Baculovirus Expression Systems, Transfection Systems, Viral Vector Purification Systems
  • 9.8. Global Cell And Gene Therapy Bio-Manufacturing Market, Sub-Segmentation Of Consumables And Reagents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cell Culture Media, Buffers And Solutions, Filtration Consumables, Chromatography Resins, Single Use Bags And Tubing, Assay And Detection Reagents
  • 9.9. Global Cell And Gene Therapy Bio-Manufacturing Market, Sub-Segmentation Of Software And Automation Platforms, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Manufacturing Execution Software, Laboratory Information Management Software, Process Monitoring Platforms, Data Analytics Platforms, Workflow Automation Systems, Quality Control Software

10. Cell And Gene Therapy Bio-Manufacturing Market Regional And Country Analysis

  • 10.1. Global Cell And Gene Therapy Bio-Manufacturing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Cell And Gene Therapy Bio-Manufacturing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Cell And Gene Therapy Bio-Manufacturing Market

  • 11.1. Asia-Pacific Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Cell And Gene Therapy Bio-Manufacturing Market

  • 12.1. China Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Cell And Gene Therapy Bio-Manufacturing Market

  • 13.1. India Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Cell And Gene Therapy Bio-Manufacturing Market

  • 14.1. Japan Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Cell And Gene Therapy Bio-Manufacturing Market

  • 15.1. Australia Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Cell And Gene Therapy Bio-Manufacturing Market

  • 16.1. Indonesia Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Cell And Gene Therapy Bio-Manufacturing Market

  • 17.1. South Korea Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Cell And Gene Therapy Bio-Manufacturing Market

  • 18.1. Taiwan Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Cell And Gene Therapy Bio-Manufacturing Market

  • 19.1. South East Asia Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Cell And Gene Therapy Bio-Manufacturing Market

  • 20.1. Western Europe Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Cell And Gene Therapy Bio-Manufacturing Market

  • 21.1. UK Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Cell And Gene Therapy Bio-Manufacturing Market

  • 22.1. Germany Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Cell And Gene Therapy Bio-Manufacturing Market

  • 23.1. France Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Cell And Gene Therapy Bio-Manufacturing Market

  • 24.1. Italy Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Cell And Gene Therapy Bio-Manufacturing Market

  • 25.1. Spain Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Cell And Gene Therapy Bio-Manufacturing Market

  • 26.1. Eastern Europe Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Cell And Gene Therapy Bio-Manufacturing Market

  • 27.1. Russia Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Cell And Gene Therapy Bio-Manufacturing Market

  • 28.1. North America Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Cell And Gene Therapy Bio-Manufacturing Market

  • 29.1. USA Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Cell And Gene Therapy Bio-Manufacturing Market

  • 30.1. Canada Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Cell And Gene Therapy Bio-Manufacturing Market

  • 31.1. South America Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Cell And Gene Therapy Bio-Manufacturing Market

  • 32.1. Brazil Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Cell And Gene Therapy Bio-Manufacturing Market

  • 33.1. Middle East Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Cell And Gene Therapy Bio-Manufacturing Market

  • 34.1. Africa Cell And Gene Therapy Bio-Manufacturing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Cell And Gene Therapy Bio-Manufacturing Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Cell And Gene Therapy Bio-Manufacturing Market Regulatory and Investment Landscape

36. Cell And Gene Therapy Bio-Manufacturing Market Competitive Landscape And Company Profiles

  • 36.1. Cell And Gene Therapy Bio-Manufacturing Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Cell And Gene Therapy Bio-Manufacturing Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Cell And Gene Therapy Bio-Manufacturing Market Company Profiles
    • 36.3.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Samsung Biologics Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis

37. Cell And Gene Therapy Bio-Manufacturing Market Other Major And Innovative Companies

  • FUJIFILM Corporation, Pfizer CentreOne, Charles River Laboratories International Inc., Boehringer Ingelheim International GmbH, Sartorius AG, Miltenyi Biotec B.V. & Co. KG, AGC Biologics LLC, Oxford Biomedica plc, Takara Bio Inc., KBI Biopharma Inc., Rentschler Biopharma SE, Minaris Regenerative Medicine GmbH, ElevateBio LLC, Forge Biologics Holdings LLC, Porton Advanced Solutions Co. Ltd.

38. Global Cell And Gene Therapy Bio-Manufacturing Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Cell And Gene Therapy Bio-Manufacturing Market

41. Cell And Gene Therapy Bio-Manufacturing Market High Potential Countries, Segments and Strategies

  • 41.1 Cell And Gene Therapy Bio-Manufacturing Market In 2030 - Countries Offering Most New Opportunities
  • 41.2 Cell And Gene Therapy Bio-Manufacturing Market In 2030 - Segments Offering Most New Opportunities
  • 41.3 Cell And Gene Therapy Bio-Manufacturing Market In 2030 - Growth Strategies
    • 41.3.1 Market Trend Based Strategies
    • 41.3.2 Competitor Strategies

42. Appendix

  • 42.1. Abbreviations
  • 42.2. Currencies
  • 42.3. Historic And Forecast Inflation Rates
  • 42.4. Research Inquiries
  • 42.5. The Business Research Company
  • 42.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기